Navigation Links
MedCom Announces Card Activation Wins Significant Court Ruling
Date:3/25/2008

SCOTTSDALE, Ariz., March 25 /PRNewswire-FirstCall/ -- MedCom USA, Inc. (OTC Bulletin Board: EMED), a leading provider of HIPAA compliant healthcare and financial transaction solutions for the healthcare industry owning approximately 40% of the issued shares of Card Activation Technologies (OTC Bulletin Board: CDVT), announced that Card Activation won a significant court ruling on March 20, 2008, in its lawsuit against major retailers Barnes & Noble, Inc. (NYSE: BKS) and Aeropostale, Inc. (NYSE: ARO). Barnes & Noble and Aeropostale sought to invalidate the Card Activation patent in that litigation. Federal District Court Judge Joan B. Gottshall entered a decision, however, refusing to accept Barnes & Noble and Aeropostale's position that Card Activation's patent is invalid.

Mark Roth of Orum & Roth LLC, one of Card Activation's attorneys, deemed the ruling very significant for Card Activation's litigation and licensing efforts. "Card Activation's victory on this motion significantly strengthens our position in this, and other cases. The court's decision furthers our belief in the strength of the patent and our claims against those entities that we have sued as well as those entities that we have contacted to discuss taking a license under the patent," said Mr. Roth.

The Card Activation patent relates to a method used by most retailers for processing debit styled cards, which include gift cards and phone cards. Card Activation currently has lawsuits pending against Walgreen Company (NYSE: WAG), Sears Holding
'/>"/>

SOURCE MedCom USA, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. MedCom Announces Court Rules Card Activation Technologies Patent Is Valid
2. MedCom USA Signs Southwood Medical Marketing to Distribute MedCom System
3. MedcomSoft Receives 2007s "Best in KLAS" EMR Ranking (1-5 Physicians)
4. MedcomSoft appoints former U.S. presidential health advisor, James Haveman, to health Care advisory board
5. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
6. Tempo Participacoes S.A. Announces Increase of 16.8% in Net Revenue and of 46.3% in EBITDA for 2007
7. Select Medical Corporation Announces Results for Fourth Quarter and Year Ended December 31, 2007
8. Health Fitness Announces $2.5 Million Stock Repurchase Plan
9. Sharps Compliance Corp. Announces Appointment of Al Aladwani as its Senior Vice President of Operations
10. Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance
11. Olympus Announces 2008 Winners of Olympus Innovation Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2008)... Biggs Named Spokesperson for Education Campaign o...lpha-1 Proteinase Inhibitor (Human) Augmentation ...USSIA, Pa., May 17 /PRNewswire/ -- Melissa Biggs, ...watch was recently named,spokesperson for an educa...ing Americans to get tested for alpha-1 antitrypsi...
(Date:5/16/2008)... BENSALEM, Pa., May 16 /PRNewswire/ -- Law Offi...eadline to move to be a lead plaintiff in the,secu... persons who,purchased or otherwise acquired the c... ("Inverness Medical" or the "Company") (Amex: IM...or about November 14, 2007 (the,"Class Period"). T...
(Date:5/16/2008)...Consumers could report side effects, but critics w...IDAY, May 16 (HealthDay News) -- Direct-to-consume...e phone number that would allow consumers to repor...ted Friday. , The experts serve on a panel that...ch phone numbers are already mandated by the FDA f...
(Date:5/16/2008)... Contract Covers More than 500 Workers, WASHIN...500 paramedics,and emergency medical technicians i...ington area have ratified their first-ever contrac...these workers are now covered by a,strong contract...ement,future," said Teamsters General President Ji...
Breaking Medicine News(10 mins):Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 2Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 3Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 4Health News:Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease 5Health News:Law Offices of Howard G. Smith Announces 24 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Inverness Medical Innovations, Inc. 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 2Health News:FDA Panel Considers Toll-Free Number for TV Drug Ads 3
...rd researchers suggests a link between the hepatit...study, people who received the vaccine were three-...hree years than those who were not vaccinated. Whi...tigators emphasize the overall effect of the vacci...
... an increased risk for life-threatening cardiovasc...etes would be well // advised to monitor their blo..., according to a new study. Researchers conducted ...ed observational studies focused on the relationsh...
...itis in asthma patients tends to be more severe an...hers suggest patients // can have dramatic improve...surgical options is used. In the study patients wi...cidence of nasal polyps, olfactory dysfunction, an...
... designed to educate parents about allergens and t...in children // say researchers .More than 900 ch... allergic to at least one indoor environmental all...earch shows children who live in these areas suffe...
Other Medicine News:
(Date:5/16/2008)...6 /- Memory Pharmaceuticals...ith several key development,programs at its R&D Da...ny,reported new clinical data for MEM 1414, its le...S activity in humans. In addition, the,Company has...date from its,5-HT6 antagonist program, and separa...
(Date:5/16/2008)... /- BioVex Inc, a biotechnology,compa...and infectious,disease, announced today that the a...ase II clinical trial of OncoVEX GM-CSF in advance...ican Society of Clinical Oncology,(ASCO) website l...abstract,which describes the data as of the submis...
(Date:5/16/2008)...al Biomarkers -- for Lung Cancer Diagnosis and, Id...er of Unknown Primary ... Types With High Sensitivity and, Specificity an...ancer Results of microRNA Signature to Identify T...eding 90% and Specificity of 99%, REHOVOT, Israel...
(Date:5/16/2008)...Statistically Significant Reductions in Selected ...tract to be published in 2008 Proceedings of the A...cal Oncology, SAN DIEGO, May 16 /PRNewswire-First...X ) announced today that, in a registrational bioe...statistically significant reduction,in general dis...
Breaking Medicine Technology:Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 2Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 3Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day 4BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 2Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 3Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 4Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 5Rosetta Genomics to Present Multiple Posters at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) 6ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5Environment Energy and Ethics conference at UD Sept 21 23 1197 1Environment Energy and Ethics conference at UD Sept 21 23 1197 2Scientists highlight benefits of genetic research in sport but warn of ethical concerns 1194 1Scientists highlight benefits of genetic research in sport but warn of ethical concerns 1194 2Scientists highlight benefits of genetic research in sport but warn of ethical concerns 1194 3Salmon garnish points the way to green electronics 377 1Salmon garnish points the way to green electronics 377 2Salmon garnish points the way to green electronics 377 3Academy releases emergency preparedness tools to enable millions more people to shelter in place 1191 1Academy releases emergency preparedness tools to enable millions more people to shelter in place 1191 2Academy releases emergency preparedness tools to enable millions more people to shelter in place 1191 3Academy releases emergency preparedness tools to enable millions more people to shelter in place 1191 4
...udy shows intramuscular injection of peramivir for...nza virus infection and,inhibited virus replicatio...uenza during a pandemic, MEMPHIS, Tenn., May 01, 2...peramivir might offer humans significant protectio...5N1, according to,results of mouse studies conduct...
...ivotal phase III study in women with recurrent ova...GTON, May 01, 2007,/PRNewswire-FirstCall/ -- A new...tion of phenoxodiol, an investigational drug being...drug appears to,work by targeting a certain tumor-...s that selectively induce cancer cell death.,Pheno...
Other Medicine Technology:Peramivir Protects Mice From Lethal H5N1 Infection 2Peramivir Protects Mice From Lethal H5N1 Infection 3New Research Results Show That Investigational Drug Phenoxodiol,Targets Cancer Protein, Causing Cancer Cell Death 2New Research Results Show That Investigational Drug Phenoxodiol,Targets Cancer Protein, Causing Cancer Cell Death 3New Research Results Show That Investigational Drug Phenoxodiol,Targets Cancer Protein, Causing Cancer Cell Death 4New Research Results Show That Investigational Drug Phenoxodiol,Targets Cancer Protein, Causing Cancer Cell Death 5
Provides stable positioning of the knee during surgery.
The kneeGRIP™ is designed to secure the position of the lower extremity with the knee flexed.
The autoLog™ Autotransfusion System processes blood collected from a surgical site to produce washed red blood cells for return to a patient at a later time. This is achieved with only one kit
...cs OrthoPAT system collects and cleanses red blood...e first product of its kind designed specifically ...loss of orthopedic surgical patients. The system c...an electromechanical device which together collect...
Medicine Products: